somatostatin receptor 4 agonists

Somatostatin receptor 4 (SST4) agonists are a class of small molecule therapeutics being developed for the treatment of chronic pain, including neuropathic and inflammatory conditions. These compounds selectively target the somatostatin receptor subtype 4 (SST4), a Gi protein-coupled receptor that mediates analgesic and anti-inflammatory effects without the endocrine side effects typically associated with other somatostatin receptor subtypes (such as SST2 or SST5). Developers such as Algonist Biotechnologies are advancing pyrrolo-pyrimidine-based agonists that demonstrate high oral bioavailability and potent anti-hyperalgesic efficacy in preclinical models. A key feature of some next-generation SST4 agonists is their biased signaling profile, which avoids β-arrestin recruitment to potentially prevent receptor desensitization and maintain long-term efficacy without the addiction risks associated with opioids.

Other names

SST4 agonistsSST-4 agonistsSST 4 agonistssomatostatin receptor subtype 4 agonistsSSTR4 agonistsSSTR-4 agonistsSSTR 4 agonists